Thymosin Alpha-1 vs KPV
Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha, registered as a prescription immunomodulator in several countries and tested in more than thirty controlled human trials. KPV is the three-residue C-terminal fragment of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13), with an evidence base that is entirely preclinical and concentrated in rodent colitis and in keratinocyte culture. They are paired in consumer material because both are promoted as anti-inflammatory or immune-modulating peptides, but no published study has administered or tested them together, in any model, in vitro or in vivo. Searches of PubMed and Europe PMC returned a single record that engages both, a 2026 narrative review that describes each separately within a survey of therapeutic peptides. Any comparison is therefore indirect, drawn from separate literatures that differ by a factor of roughly thirty in molecular size, by species, by route and by whether human data exist at all.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published study has administered or tested thymosin alpha-1 and KPV in the same experiment, in any species or cell system. Searches of PubMed field indexes and of Europe PMC full text returned no comparative work and no shared model. The only located publication that engages both is a 2026 narrative review of therapeutic peptides in aesthetic, metabolic and endocrine practice, which groups them within a section on peptides derived from the gastrointestinal tract and thymus and then describes each on its own citations. Every comparison between the two is therefore assembled from separate studies that used different species, different routes of delivery, different endpoints and different eras of methodology. The gap is particularly wide because the two literatures are not the same kind of literature: thymosin alpha-1 has been examined in randomised controlled trials with mortality and virological endpoints, while KPV has been examined in rodent colitis models and cultured keratinocytes, increasingly through engineered delivery vehicles rather than as the free peptide.
The publication that covers both
- 01Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.
Renke G, Chinellato L, et al. · International Journal of Molecular Sciences · narrative review of therapeutic peptides used or investigated in aesthetic, metabolic and endocrine practice, including a section on peptides of gastrointestinal and thymic origin
The review grouped thymosin alpha-1 and KPV within the same section on peptides derived from the gastrointestinal tract and thymus, alongside BPC-157, thymosin beta-4, GHK-Cu and LL-37. KPV was described as a short anti-inflammatory fragment of alpha-melanocyte-stimulating hormone taken up in intestinal epithelial cells and T cells through the PepT1 transporter, suppressing NF-kappaB and MAPK signalling, reducing disease severity and histologic damage in preclinical colitis and reducing tumour number and size in a colitis-associated cancer model. Thymosin alpha-1 was cited in the context of restoring immune homeostasis in lymphocytes after SARS-CoV-2 infection. The authors administered nothing and drew no comparison between the two.
Side by side.
| Thymosin Alpha-1 | KPV | |
|---|---|---|
| Evidence maturity | Approved drug | Preclinical only |
| Studies cited here | 16 | 15 |
| Published 2023 or later | 11 | 6 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A 28-amino-acid peptide derived from prothymosin alpha and originally isolated from thymic tissue, with a described endogenous role in T-cell maturation. | A tripeptide, lysine-proline-valine, corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone, alpha-MSH(11-13). It is a fragment of a larger endogenous hormone rather than a signalling molecule with an independently established physiological role. |
| Mechanism as described in the literature | Acts largely through Toll-like receptor signalling on dendritic cells and monocytes, influencing T-cell differentiation, thymic output and cytokine balance. | Taken up by intestinal epithelial cells and T cells through the PepT1 di- and tripeptide transporter, where published work reports suppression of NF-kappaB signalling and reduced pro-inflammatory cytokine output, plus barrier-protective effects in keratinocytes. |
| Size of the evidence base | Sixteen verified studies in this library, of which nine are human clinical trials and five are systematic reviews or meta-analyses. | Fifteen verified studies, of which ten are rodent in vivo experiments, three are in vitro and two are reviews. None is a human clinical trial. |
| Best-characterised finding | Immune reconstitution and infection-related endpoints in chronic hepatitis B, sepsis, severe acute pancreatitis and oncology adjuvant settings, reported across repeated randomised trials. | Reduced colitis severity in murine and rat models after oral or rectal delivery, with lower histologic damage scores and reduced cytokine expression, and reduced tumour number and size in a PepT1-dependent colitis-associated cancer model. |
| Human data | More than thirty controlled trials. The phase 3 TESTS study found no mortality benefit in sepsis, and the pooled meta-analytic signal weakens when analysis is restricted to high-quality multicentre trials; positive small trials and null large trials recur across pancreatitis and hepatitis B cirrhosis. | None. No human clinical trial of KPV has been published for colitis, wound healing, skin inflammation or any other indication, so effective human route and safety profile are unknown. |
| Identity of the marketed molecule | The peptide studied in the trials is the same 28-residue molecule that is supplied, so the literature and the product describe one substance. | Most recent efficacy results were generated with KPV inside engineered carriers designed to stabilise and target it. Results from those formulations do not transfer to unformulated KPV, which is what is sold. |
| Regulatory status | Registered as a prescription immunomodulator in a number of countries, principally for chronic hepatitis B. Not approved by the FDA or EMA. | No approved formulation in any jurisdiction, and no registered clinical trial reported in the indexed literature. |
| Basis of most marketing claims | Extrapolation from prescription immunomodulation in infection and oncology to general immune support and healthy ageing, for which no controlled human trial exists. | Extrapolation from rodent colitis models and from the wider alpha-MSH literature to human gut, skin and systemic anti-inflammatory use, across a species gap and a formulation gap at the same time. |
And what it does not.
Nothing in the published record establishes how these two peptides compare, because no experiment has run them side by side. What the separate literatures support is asymmetric rather than contradictory. Thymosin alpha-1 has been through more than thirty controlled human trials and is a registered prescription immunomodulator in several countries, yet its largest and most rigorous trial in sepsis was null and the meta-analytic signal weakens as trial quality rises. KPV has no human trial at all; its record consists of rodent colitis experiments, keratinocyte culture work and, increasingly, formulation studies in which the peptide is carried inside a hydrogel or nanoparticle. Both are described as anti-inflammatory, but through different mechanisms, in different compartments, at different levels of evidence. A reader looking for a published basis to prefer one over the other for a shared indication will not find one, because the two have never been tested against a shared endpoint.
Common questions.
- Is there any published experiment that used both thymosin alpha-1 and KPV?
No. Searches of PubMed field indexes and Europe PMC full text returned no study that administered or tested both, in any species or cell system. The only located publication that engages both is a 2026 narrative review of therapeutic peptides, which places them in the same section on peptides of gastrointestinal and thymic origin and then describes each from its own separate citations. The review conducted no experiment and drew no comparison between them.
- Why is KPV described as preclinical only when thymosin alpha-1 is a registered drug?
The two have travelled very different distances. Thymosin alpha-1 has been through randomised trials with mortality, virological and immune endpoints and is registered as a prescription immunomodulator in several countries. KPV has never been tested in a published human clinical trial for any indication, so effective human route, exposure and safety profile remain unknown. Its evidence consists of rodent colitis models, keratinocyte culture and formulation science rather than clinical research.
- Do the two act on the same part of the immune system?
Not as described in the literature. Thymosin alpha-1 is reported to act through Toll-like receptor signalling on dendritic cells and monocytes, shaping T-cell differentiation and thymic output, which is a systemic and adaptive-immunity account. KPV is reported to enter intestinal epithelial cells and T cells through the PepT1 transporter and to suppress NF-kappaB signalling locally, which is a mucosal and innate-inflammation account. The overlap is the word anti-inflammatory rather than a shared pathway.
- Does the rodent colitis evidence for KPV say anything about human use?
It establishes a mechanism worth testing and nothing more. The colitis experiments were conducted in mice and rats, several of them with the peptide delivered inside hyaluronic acid nanoparticles or mucoadhesive hydrogels built specifically to stabilise it. Free KPV is unstable in aqueous and rectal administration, which is why the recent work uses carriers. Results obtained with an engineered vehicle do not transfer to the unformulated peptide, and no human trial has been run.
- Which compound has the better safety record?
Only one of them has a record. Thymosin alpha-1 has been given to substantial numbers of trial participants across hepatitis B, sepsis, pancreatitis and oncology, so adverse events have been collected under trial conditions in several countries. KPV has no published human exposure data at all, which is not the same as a clean safety profile; it means the question has not been asked. Absence of reported harm in rodents does not establish human tolerability.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.